New York, NY, June 22, 2026 (GLOBE NEWSWIRE) — Matrix Applications, a leading provider of financial technology and operational solutions in the capital markets, marks its fourth year earning accreditation from the Better Business Bureau (BBB), a nonprofit organization dedicated to advancing marketplace trust by holding businesses to high standards of ethical conduct, accountability and customer care.
Autonomous Data Platform Market Projected to Reach $22.34 Billion by 2035 | SNS Insider
The U.S. Autonomous Data Platform Market is Anticipated to Touch $5.77 Billion by 2035, While Europe is Expected to Expand from $0.69 Billion to $5.10 Billion, Driven by Rising Demand for Real-Time Analytics, AI-Powered Decision-Making, Cloud Adoption, and Enterprise Digital Transformation Across BFSI, Healthcare, Manufacturing, and Retail Sectors
The U.S. Autonomous Data Platform Market is Anticipated to Touch $5.77 Billion by 2035, While Europe is Expected to Expand from $0.69 Billion to $5.10 Billion, Driven by Rising Demand for Real-Time Analytics, AI-Powered Decision-Making, Cloud Adoption, and Enterprise Digital Transformation Across BFSI, Healthcare, Manufacturing, and Retail Sectors
Sharplink Announces Pricing of $75 Million Registered Direct Offering Priced at Approximately 41% Premium to Last Closing Share Price
MIAMI, June 22, 2026 (GLOBE NEWSWIRE) — Sharplink, Inc. (Nasdaq: SBET) (“Sharplink” or the “Company”), one of the world’s largest corporate holders of Ether (“ETH”) and a prominent industry advocate of Ethereum adoption, today announced that it has entered into a securities purchase agreement with an institutional investor (the “Investor”) for the purchase and sale of 10,013,351 shares of its common stock, par value $0.0001 per share (the “Shares), and accompanying warrants to purchase up to 10,013,351 shares of common stock (the “Warrants”), at a combined purchase price of $7.49 per Share and Warrant. The purchase price represents a 41% premium to the Company’s closing share price of $5.29 on June 18, 2026 (the “Closing Share Price”), as reported on the Nasdaq Capital Market, and a premium to the net asset value (“NAV”) of Sharplink’s ETH holdings1 reported as of June 16, 2026 of 875,776 ETH. The Warrants will have an exercise price of $8.15 per Share, will be exercisable immediately upon issuance, and will expire four (4) years from the date of issuance.
Arms Cyber provides additional hardening for Veeam Environments with Immutable Shield, Anti-Tamper Controls, and Process Validation
New stealth-driven capabilities purpose-built for Veeam environments to shield backup data, services, and execution paths from the ransomware groups now targeting backup infrastructure directly.
New stealth-driven capabilities purpose-built for Veeam environments to shield backup data, services, and execution paths from the ransomware groups now targeting backup infrastructure directly.
Yes& Acquires Modo Modo, Expanding B2B Marketing and Atlanta Presence
ATLANTA, GA, June 22, 2026 (GLOBE NEWSWIRE) — Yes& has acquired Modo Modo, a B2B-focused agency recognized for its work across healthcare, fintech, manufacturing, energy and technology sectors.
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) — Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1.
Saratoga Investment Corp. to Report Fiscal First Quarter 2027 Financial Results and Hold Conference Call
NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR), a business development company, will report its financial results for the fiscal quarter ended May 31, 2026, on Tuesday July 7, 2026, after market close. A conference call to discuss the financial results will be held on Wednesday July 8, 2026. Details for the conference call are provided below.
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 – the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug Application (NDA) for EB613
Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
MITOLINE®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).
Outdoor Holding Company Reports Fourth Quarter and Fiscal Year 2026 Financial Results
Atlanta, Ga., June 22, 2026 (GLOBE NEWSWIRE) — Outdoor Holding Company (Nasdaq: POWW, POWWP) (“OHC,” “we,” “us,” “our” or the “Company”), the owner of GunBroker.com, the largest online marketplace dedicated to firearms, hunting, shooting, and related products, today reported its financial results for its fourth fiscal quarter and year ended March 31, 2026.
Firm Capital Property Trust Announces Completion of Competition Bureau of Canada Inquiry Regarding Acquisition of 50% Interests in Ten Manufactured Home Communities for $218 Million
Expected Closing Set for Q3/2026
Expected Closing Set for Q3/2026
Chevron Strikes Power Deal With Microsoft for West Texas AI Data Center
The 2.7-gigawatt project will have its own on-site power plant fueled by Chevron’s local natural-gas production.
Kandi Technologies Accelerates Global Expansion
Kandi’s International Off-Road Vehicle Business Reaches Customers in 35 Countries and Regions, Expanding in Africa, Southeast Asia, Latin America and the Middle East Alongside Robust Momentum in the North American Market
EagleNXT Secures Order of eBee VISION ISR and eBee TAC Systems from Asia Pacific Customer
Two eBee VISION and three eBee TAC drones to support advanced ISR, tactical mapping, and operational readiness in the region
Country Stampede Breaks Attendance Records
Limited ticket inventory remaining
Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease Biomarkers
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, June 22, 2026 (GLOBE NEWSWIRE) — Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs. and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a collaboration between DiamiR and AlzLabs Precision Diagnostics (“AlzLabs”) to generate protein and microRNA blood-based biomarker data with the focus on Alzheimer’s disease.
Notice: Australian Pokie Hub Highlights Upcoming Pokie Releases and Industry Trends
Sydney, New South Wales, AUSTRALIA, June 22, 2026 (GLOBE NEWSWIRE) —
Australian Pokie Hub has published an informational overview discussing upcoming pokie releases and emerging trends in online slot game development. The announcement outlines gameplay innovations, design trends, and features that players may encounter in future titles from established game studios.
Medical Affairs Outsourcing Market Size to Surpass USD 4.18 Billion by 2035 | SNS Insider
The U.S. Medical Affairs Outsourcing Market is projected to grow from USD 0.64 Billion in 2025 to USD 1.06 Billion by 2035, while Europe is expected to expand from USD 0.67 Billion to USD 2.41 Billion, supported by increasing clinical trial complexity, regulatory requirements, and pharmacovigilance outsourcing demand.
The U.S. Medical Affairs Outsourcing Market is projected to grow from USD 0.64 Billion in 2025 to USD 1.06 Billion by 2035, while Europe is expected to expand from USD 0.67 Billion to USD 2.41 Billion, supported by increasing clinical trial complexity, regulatory requirements, and pharmacovigilance outsourcing demand.